Clinical reference Biomarker Directory
Back to directory

5-HIAA

Established

5-HIAA is the classic biochemical marker for diagnosing and monitoring carcinoid syndrome from serotonin-secreting neuroendocrine tumors.

Also known as 5-HIAA 5-hydroxyindoleacetic acid
In plain language

5-HIAA is a breakdown product of serotonin, and measuring it is the classic way to diagnose carcinoid syndrome, a hormone-related condition from certain gut tumors. The traditional test requires an inconvenient full-day urine collection, but a simple blood test has recently been shown to work just as well, which could make this much easier for patients going forward.

Biomarker & context

5-Hydroxyindoleacetic acid (5-HIAA) is the primary metabolite of serotonin, and its measurement is the classic biochemical test for diagnosing carcinoid syndrome, connecting directly to the chromogranin A, gastrin, VIP, and other neuroendocrine tumor markers discussed elsewhere in this biomarker set.

What it indicates

Elevated 5-HIAA confirms serotonin overproduction, most often from midgut (small intestinal) neuroendocrine tumors causing carcinoid syndrome (flushing, diarrhea, and in advanced cases, carcinoid heart disease); higher levels correlate with worse prognosis and increased risk of carcinoid heart disease development.

Diagnosis & clinical testing

Traditionally measured via 24-hour urine collection, with reported sensitivity and specificity of roughly 73-100% and 85-100% respectively depending on the study; a genuinely useful recent development is that serum 5-HIAA (a single blood draw) has been shown to perform equivalently to the 24-hour urine collection, offering a far more convenient alternative that avoids the well-known problems of incomplete collection and dietary/medication interference.

Guiding treatment

Patients must avoid serotonin-rich foods (bananas, walnuts, pineapple, tomatoes, plums) and certain medications before testing, since these cause false elevations; serial 5-HIAA monitoring during treatment helps track disease progression, and a shortening doubling time signals higher risk of progression or death, directly informing surveillance intensity.

Clinical significance

A 2025 study shows serum 5-HIAA (single blood draw) performs equivalently to the traditional, more burdensome 24-hour urine collection.

References
  1. PMC. (2023). Urinary 5-Hydroxyindolacetic Acid Measurements in Patients with Neuroendocrine Tumor-Related Carcinoid Syndrome: State of the Art.
  2. Journal of Clinical Endocrinology & Metabolism. (2025). Serum 5-Hydroxyindoleacetic Acid Measurements for the Diagnosis and Follow-up of Carcinoid Syndrome.